Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSanam LoghaviFHFadi HaddadGBGautam Borthakur

Discussion

Loading...

Member takes

Overview

Machine learning reveals a blood protein signature improves prognostic value in TP53-mutated AML, indicating potential for targeted therapy.

Key Points

  • This research aims to improve survival prognostication in TP53-mutated acute myeloid leukemia using a blood-based protein signature.
  • Collected serum samples from patients with TP53-mutated AML prior to therapy.
  • Quantified 251 inflammatory proteins using the NULISA platform.
  • Employed a machine learning pipeline to identify key proteins associated with survival.
  • Developed a risk stratification model based on Cox proportional hazards analysis of selected proteins.
  • Validated findings against an established genomic risk model.
  • Identified 13 circulating proteins that predict survival outcomes for TP53-mutated AML.
  • The protein signature provided a hazard ratio of 2.31 for death between high- and low-risk groups.
  • The combination of protein data with the genomic model yielded a higher hazard ratio of 3.02 for risk stratification.
  • The median overall survival was 3 months for high-risk patients compared to 10 months in the low-risk group.

Cite This Study

Loghavi et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da40https://doi.org/10.1182/blood-2025-3503
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of a prognostic signature based on expression of post-translational modification-related genes in acute myeloid leukemia2026
  2. 2Abstract IA010: TP53-independent risk stratification in mantle cell lymphoma using a novel gene expression signature2026
  3. 3TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.2026
  4. 4Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML2025
  5. 5Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.2025 · 1 citations